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Abstract
Background: Nitric oxide (NO) is an endothelium derived relaxing factor (EDRF) which has an important role
for regulating the heart-vessel physiology. The objective of this study was to evaluate the effects of the eNOS T-
786C polymorphism on lipid parameters and the development of acute coronary syndrome (ACS) and coronary
heart disease (CHD) for the first time in a Turkish study group. We have analyzed the genotype frequencies of
the T-786C polymorphism of the eNOS gene in 10 ACS patients (5 men, 5 women), 20 CHD patients (14 men,
6 women), and 31 controls (10 men, 21 women), who were angiographically proven to have normal coronaries.
Results: The demographic, biochemical and left ventricule systolic dysfunction data of the ACS, CHD patients
and controls were analyzed as a function of eNOS T-786C genotypes. The eNOS gene T-786C polymorphism
frequencies for T/T, C/T and C/C genotypes were respectively 10%, 40%, 50% in subjects with ACS; 75%, 20%,
5% in subjects with CHD and 67.7%, 25.8%, 6.5% in the control group. Significant difference was observed in
genotype frequencies between the study groups for T-786C polymorphism (p = 0.001). The CC genotype
frequency was found to be the most prevalent in ACS group in comparison to CHD and control groups (p =
0.001). TT was the most frequently observed genotype in both CHD patients and controls (p = 0.001). Left
ventricule systolic dysfunction frequency was found to be highest in C/T genotype carriers (66.7%) in patients
(ACS+CHD). None of the patients with LVSD were carrying the normal genotype (T/T). The eNOS T-786C
polymorphism was not found to be effective over any analyzed lipid variable in patients (ACS+CHD). The HDL-
cholesterol levels were found to be lower in CHD group were compared to controls (p < 0.01), whereas glucose
and leucocyte levels of the ACS and CHD groups were both higher than controls (p < 0.001).
Conclusion: The significantly high frequency of eNOS -786C/C genotype in ACS patients than in those of
controls, indicate the genotype association with ACS. The finding of significantly high frequency of T/T genotype
in the CHD group, may support the relationship of CC genotype with ACS without CHD. The high frequency of
the mutant (C/C) and heterozygous (C/T) genotypes found may be linked to left ventricule remodeling after MI.
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Background
Nitric oxide (NO) is a key factor in the antiatherosclerotic
properties of the endothelium. NO regulates vascular
smooth muscle cell proliferation and migration, vascular
tone, endothelial permeability, and endothelial-leucocyte
interaction, and has antithrombotic effects [1-4]. Genetic
polymorphisms of eNOS have been shown to have a sig-
nificant effect on NO levels, plasma lipids and have been
associated with T2DM [5], heart failure [6], coronary
spasm [7], atherosclerosis [8], myocardial infarction [9],
coronary in-stent restenosis [10] and hypertension [9] in
some studies. Because of the pleiotrophic effects of NO,
various studies have investigated the link between poly-
morphisms of the endothelial nitric oxide synthase
(eNOS) gene and the development of coronary events.
Among the many reported polymorphisms of the eNOS
gene, two polymorphisms, namely the Glu298Asp(G:T)
polymorphism located in exon 7, and T-786C in pro-
moter have received much interest with respect to the pos-
sible association between such polymorphisms and
coronary artery disease (CAD) [11,12]. In the present
study, we sought to evaluate the effects of the eNOS T-




We studied 10 ACS patients (5 men, 5 women), 20 CHD
patients (14 men, 6 women), and 31 controls (10 men, 21
women), who were angiographically proven to have nor-
mal coronaries from Group Florence Nightingale Hospital
(Istanbul, Turkey). Patients who had unstable angina pec-
toris (USAP), ST-elevation myocardial infarction (STEMI)
and non-STEMI (NSTEMI) were referred as ACS. All the
ACS patients had chest pain longer than 20 min, in resting
state. All ACS patients serum cardiac enzymes (troponin
T, creatine kinase-MB subforms) were high. All ACS
patients has ischaemic ST-T changes on electrocardiogra-
phy. The criteria for CHD was narrowing of artery 50% or
more with angiography, who had stable angina pectoris
and who were ischaemia positive with noninvasive tests.
Left ventricule systolic functions were evaluated with
echocardiography. Patients with ejection fraction (EF)
between 35 and 50 were accepted to have moderate left
ventricule systolic dysfunction (LVSD), whereas below 35
was accepted as severe LVSD. Since only 2 patients had
severe LVSD, only 1 patient with moderate LVSD were
included in the statistical analysis. The mean EF of the
patiens (ACS+ CHD) was 37.4 ± 1.85. Conventional risk
factors for CHD such as dyslipidemia (HDL-cholesterol
levels <45 mg/dl, triglyceride levels >150 mg/dl and LDL-
cholesterol levels>130 mg/dl), hypertension (blood pres-
sure > 130/80 or prior therapy), diabetes mellitus (fasting
blood glucose of >120 mg/dl or prior therapy), obesity
(BMI >25), positive family history for CHD and smoking
(current smokers) were obtained by viewing records and
interviewing patients. The mean age was 60.20 ± 2.52 for
ACS patients, 60.70 ± 1.99 for CHD patients and 59.00 ±
1.68 for controls. Written consent was taken from each
patient following a full explanation of the study, which
has been approved by the Ethics Committee of the Istan-
bul Science University. The study groups were matched for
age, as well as social and economic status.
Subjects with secondary hypertension (renal artery steno-
sis, glomerulonephritis), diabetic nephropathy (Kimmel-
stiel-Wilson syndrome), hypertension with
endocrinopathies (phoechromocytoma, Cushing syn-
drome, hyper and hypothyroidism), patients with pseu-
dohypertension, neoplasia and those who take oral
contraceptives and illicit drugs were not included in the
study.
Analytical methods
The plasma glucose concentration was measured by the
glucose oxidase method using Kit of Biotrol on Bayer/
opeRA analyser. Serum Total-Cholesterol was measured
using commercial kit of Biotrol; HDL-Cholesterol using
by commercial Randox's kit; LDL-Cholesterol was calcu-
lated by the formula of Friedewald) and triglyceride deter-
mination was made by the method of lipase/glycerol
kinase UV endpoint on opeRA analyser.
DNA Extraction and Genotyping
Blood was drawn from the antecubital vein into EDTA.
Genomic DNA was extracted from leukocytes by a salting
out procedure [13]. Polymerase chain reaction (PCR) and
restriction fragment length polymorphism analysis was
used for genotyping T-786C polymorphism [14]. Geno-
typing was conducted in a blinded fashion. A total of 10%
of samples were subject to repeat PCR and genotyping,
and no discrepancies were detected.
Statistical analysis
Statistical analyses were conducted using the Unistat 5.1
software program. Data were expressed as means ± SE.
Baseline differences between patients and controls were
examined by Student t-test. Hardy-Weinberg equilibrium
for genotype frequencies was estimated by the Chi-square
test. The Bonferroni correction for multiple testing was
applied as required. P values less than 0.05 were consid-
ered significant.
Results
The clinical characteristics of ACS patients, CHD patients
and control subjects were compared in Table 1. Groups
were statistically different when compared with chi-
square test with respect to hypertension (p = 0.0001), dia-
betes mellitus (p = 0.0001), dyslipidemia (p = 0.009),
heredity (p = 0.0001), recent myocardial infarction (MI)Lipids in Health and Disease 2008, 7:5 http://www.lipidworld.com/content/7/1/5
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(p = 0.002), left ventricule systolic dysfunction (p =
0.0001), left ventricule diastolic dysfunction (p = 0.016)
and left ventricule hypertrophy (p = 0.004) (Table 1).
The genotype frequency distributions of ACS, CHD
patients and 31 control subjects with respect to T-786C
polymorphism was compared in Table 2. The eNOS gene
T-786C polymorphism frequencies for T/T, C/T and C/C
genotypes were respectively 10%, 40%, 50% in subjects
with ACS; 75%, 20%, 5% in subjects with CHD and
67.7%, 25.8%, 6.5% in the control group. Significant dif-
ference was observed in genotype frequencies between the
study groups for T-786C polymorphism (p = 0.001). In
detail, when the ACS, CHD and control groups were com-
pared with respect to eNOS T-786C genotypes, the CC
genotype frequency was found to be the most prevalent in
ACS group in comparison to CHD and control groups (p
= 0.001). Whereas TT was the most frequently observed
genotype in both CHD patients controls (p = 0.001).
Distribution of left ventricule systolic dysfunction (LVSD)
in ACS and CHD patients as a function of eNOS gene T-
786C genotypes were presented in Table 3. Left ventricule
systolic dysfunction frequency was found to be highest in
C/T genotype carriers (66.7%) in patients (ACS+CHD).
None of the patients with LVSD were carrying the normal
genotype (T/T) (Table 3).
The demographic and biochemical data of the ACS
patients, CHD patients and control subjects were given in
Table 4. The HDL-cholesterol levels were found to be
lower in CHD group were compared to controls (p <
0.01), whereas glucose and leucocyte levels of the ACS
and CHD groups were both higher than controls (p <
0.001) (Table 4).
The lipid parameters of the patients (ACS+CHD) are com-
pared in Table 5 as a function of eNOS T-786C genotypes.
The eNOS T-786C polymorphism was not found to be
effective over any analyzed lipid variable (Table 5).
Discussion
Investigations into the relation between eNOS gene poly-
morphism with ACS and CAD have given various and
sometimes contradictory results. Fatini et al. [15] pro-
vided evidence that the -786CC pattern modulates the
susceptibility to ACS in 4a4a homozygotes and in hyper-
homocysteinemic patients. In the Ukrainian population
Dosenko et al. [16] showed that the CC genotype of the T-
786C polymorphism were found 2.7 times more often in
ACS patients than in controls, and thus considered its
allelic polymorphism as one of genetic risk factors of ACS
development. The findings of Nakayama et al.[17] have
strongly suggested that the CC variant in the T-786C pol-
ymorphism of eNOS gene reduced the eNO synthesis and
Table 3: Distribution of left ventricule systolic dysfunction in 
acute coronary syndrome and coronary heart disease patients as 
a function of eNOS gene T-786C genotypes
eNOS gene T-786C genotypes
T/T;n(%) C/T;n(%) C/C;n(%)
LVSD 0 (0) 4 (66.7) 2 (33.3)
LVSD: Left ventricule systolic dysfunction. Genotype frequencies were 
compared with χ2 test. p = 0.011. 2 patients with severe LVSD 
(Ejection fraction <35) were not included in the analysis. Only 1 
patient with moderate LVSD (Ejection fraction between 35–50) were 
included.
Table 2: Endothelial nitric oxide synthase gene T-786C genotype 
frequencies in acute coronary syndrome and coronary heart 
disease patients and control subjects
eNOS gene T-786C genotypes
T/T;n(%) C/T;n(%) C/C;n(%)
Acute coronary syndrome 1(10) 4(40) 5(50)*
Coronary heart disease 15(75)* 4(20) 1(5)
Control 21(67.7)* 8(25.8) 2(6.5)
Genotype frequencies were compared with χ2 test. * p = 0.001.
Table 1: Clinical characteristics of acute coronary syndrome and coronary heart disease patients and control subjects
ACS n(%) CHD n(%) Controls n(%) p
Hypertension 9 (90.0) 15 (75.0) 2 (6.5) 0.0001
Diabetes mellitus 4 (40.0) 10 (50.0) 0 (0) 0.0001
Dyslipidemia 9 (90.0) 10 (50.0) 10 (34.5) 0.009
Obesity 1 (20.0) 8 (57.1) 15 (50.0) 0.40
Smokers 4 (40.0) 12 (60.0) 9 (29.0) 0.10
Heredity 7 (70.0) 10 (50.0) 1 (3.2) 0.0001
Recent myocardial infarction 4 (40.0) 2 (10.0) 0 (0) 0.002
Left ventricule systolic dysfunction 4 (40.0) 2 (10.0) 0 (0) 0.0001
Left ventricule diastolic dysfunction 9 (90.0) 16 (80.0) 0 (0) 0.016
Left ventricule hypertrophy 3 (30.0) 4 (20) 0 (0) 0.004
The variables were compared with χ2 test among groups.Lipids in Health and Disease 2008, 7:5 http://www.lipidworld.com/content/7/1/5
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predisposes the patients with the mutation to coronary
spasm. Additionally the T-786C polymorphism in combi-
nation with smoking have been reported to increase the
risk of coronary spasm in several studies in Japanese
patients [18,19]. In another study of Nakayama et al. [20],
the frequency of the T-786C mutation was found to be sig-
nificantly higher in MI patients with no stenosed vessels
(50%) than in those with stenosed vessels (p < 0.003),
and concluded the T-786C mutation in strong association
with MI, especially without coronary arterial stenosis, in
Japanese patients. In the present study, the frequency of
eNOS -786C/C genotype was found to be significantly
higher in ACS patients (50%) than in those of controls
(6.5%), which indicate the association of -786C/C geno-
type with ACS. Our finding of significantly high frequency
of T/T genotype in the CHD group, may support the rela-
tionship of CC genotype with ACS without CHD.
Alvarez et al. [21] found eNOS-CC+ACE-DD at a higher
risk for early CAD, whereas the GENICA study performed
on Caucasions have found the C allele to be associated
with increased risk of multivessel CAD [22]. A follow up
GENICA cohort study [23] performed on high risk CAD
patients evaluating cardiovascular mortality found that,
the T-786C SNP in the promoter of eNOS beared inde-
pendent prognostic information with oxidant stres mark-
ers. A meta analysis performed over 26 studies involving
23028 subjects reported lack of influence of T-786C vari-
ant on ischaemic heart disease (IHD) risk, but a very small
effect of the variant cannot be excluded, since they found
only a 73% power to detect an OR of 1.2 at a significance
level of 5% [24]. Gomma et al. [10] have reported T-786C
polymorphism to be associated with coronary in-stent res-
tenosis in patients with CAD. In detail, they found that
carriers of the -786C allele of the eNOS T-786C polymor-
phism showed a higher frequency of restenosis [10]. In
another study, C allele homozygosity in position -786 of
the eNOS promoter has been detected to be an independ-
ent risk factor for moderate to severe internal carotid
artery stenosis, especially ulcerative lesions [25]. In our
study, the mutant genotype (CC) frequency of T-786C
polymorphism was found in low percentage (5%) to that
of wild type (TT) (75%) and heterozygous (CT) (20%),
which indicates that no association persists between T-
786C variation and CHD whereas, the frequency distribu-
tions of eNOS T-786C genotypes were similar in CHD and
control groups in the present study. In a study performed
on Japanese population [19] composed of 209 men and
238 women, the frequencies of coronary spasm respec-
tively in non-smokers with C/T or CC genotype was found
to be 61% for male and 78% for females; wheras smokers
with C/T or CC genotype was found to be 91% for male
and 92% for females, which clearly demonstrated the T-
786C polymorphism and smoking in combination
increasing the risk of coronary spasm. In our study the
eNOS T-786C genotype frequencies were not found to dif-
fer significantly with respect to smoking in none of the
study groups analyzed (data not included).
In 1106 caucasion multivessel CAD patients Rossi et al.
[22] reported T-786C T/T, T/C and C/C genotype frequen-
cies to be %41.9, %40.4 and %17.7. Alvarez et al. [21]
Table 5: Associations of lipid parameters with endothelial nitric oxide synthase gene eNOS T-786C genotypes in the patiens (acute 
coronary syndrome and coronary heart disease patients)
eNOS T-786C genotypes
T/T (n = 16) C/T (n = 8) C/C (n = 6)
Total-cholesterol (mg/dl) 207.00 ± 39.81 216.75 ± 42.38 210.83 ± 70.63
HDL-cholesterol (mg/dl) 41.07 ± 13.60 38.50 ± 9.46 42.33 ± 12.69
LDL-cholesterol (mg/dl) 138.07 ± 41.48 134.63 ± 24.52 130.33 ± 53.46
Triglyceride (mg/dl) 164.13 ± 83.70 151.88 ± 53.54 165.67 ± 64.53
Table 4: Demographic and biochemical data of the acute coronary syndrome and coronary heart disease patients and control subjects
ACS CHD Control
BMI (kg/m2) 26.50 ± 1.69 28.97 ± 1.26 26.04 ± 0.75
Glucose (mg/dl) 134.13 ± 26.21 b 126.80 ± 9.95b 66.97 ± 2.26
Leucocyte (count/mm3) 10466.67 ± 1075.48 b 8825.88 ± 426.73 b 4946.77 ± 154.92
Total-cholesterol (mg/dl) 216.10 ± 15.84 207.53 ± 10.42 198.69 ± 8.70
HDL-cholesterol (mg/dl) 43.70 ± 4,50 39.00 ± 2.29a 47.11 ± 1.87
LDL-cholesterol (mg/dl) 136.90 ± 12.54 134.79 ± 9.16 125.89 ± 7.48
Triglyceride (mg/dl) 152.50 ± 18.08 168.74 ± 17.87 137.14 ± 9.27
Values are represented as mean ± SD. a: p < 0.01 in comparison to control group, b: p < 0.001 in comparison to control groupLipids in Health and Disease 2008, 7:5 http://www.lipidworld.com/content/7/1/5
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reported a significant increase in CC genotype frequency
in comparison to C/T and TT in CAD patients. Jeeroobur-
khan et al. [26] reported significant difference among T-
786C genotypes. In detail, the T/T, T/C and C/C genotype
frequencies were found to be respectively as %37.7,
%47.8 and %14.5 in 3052 middle aged British men ini-
tially free of IHD. According to the data of Jeerooburkhan
et al. [26] no influence was found between eNOS T-786C
polymorphism and the risk of IHD as a result of 8.1 years
follow up. Neither Poirier et al. [27] in the French popu-
lation nor Granath et al. [28] in the Australian Caucasion
population did not find significant difference among
CAD cases and controls with respect to eNOS T-786C gen-
otype frequencies. Similar to the results of Poirier et al.
[27] and Granath et al. [28] we did not observe any signif-
icant difference among CAD cases and controls with
respect to eNOS T-786C genotype frequencies.
Nitric oxide can modulate many of the processes leading
to ventricular remodeling [29]. Endothelium-derived NO
causes systemic vascular relaxation [30], thereby reducing
cardiac preload and afterload. Recent evidence suggests
that NO can increase angiogenesis, decrease cardiac fibro-
sis, and decrease angiotensin II-induced cardiac myocyte
hypertrophy [31], all of which could limit ventricular
remodeling after MI. Recently, a eNOS gene polymor-
phism, G894T, which alters enzyme function [32,33], was
associated with an increased risk of CAD [34]. Scherrer-
Crosbie et al. [35] have reported the importance of eNOS
in limiting LV dilatation, dysfunction, and hypertrophy in
murine MI, possibly by limiting the hypertrophic
response to MI, and they suggest new strategies for pre-
venting detrimental LV remodeling in patients after MI. In
the present study, ACS and CHD patients LVSD with ejec-
tion fraction between 35–50%, the eNOS gene -786T/T
wild type genotype was not observed, whereas the hetero-
zygous genotype, -786C/T genotype frequency found in
highest (66.7%). Since the limitation of this study was the
relatively small sample size, the study should be repli-
cated with a larger sample.
In conclusion, The significantly high frequency of eNOS -
786C/C genotype in ACS patients than in those of con-
trols, indicate the genotype association with ACS. In addi-
tion, the finding of significantly high frequency of T/T
genotype in the CHD group, may support the relationship
of CC genotype with ACS without CHD. The high fre-
quency of the mutant (C/C) and heterozygous (C/T) gen-
otypes found may be linked to left ventricule remodeling
after MI. These findings imply that, although the mecha-
nism underlying the association between the eNOS gene
polymorphism and ACS has so far remained elusive, the
genetic background controlling nitric oxide may be asso-
ciated with the pathogenesis of ACS.
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